Revolutionizing IVF: How Israel’s IMMA Health is Making Fertility Care Smarter and More Accessible

In-vitro fertilization (IVF) has long been a demanding journey, requiring frequent, often inconvenient trips to clinics for transvaginal ultrasounds to monitor ovarian response. For decades, this critical step in fertility treatment has placed enormous physical and emotional strain on patients, while burdening clinics with heavy workloads and scheduling bottlenecks. Now, Israeli startup IMMA Health is challenging this status quo with a groundbreaking solution: the world’s first robotic, self-operated transvaginal ultrasound system designed for at-home use by women undergoing IVF. By putting patients in control of their monitoring, IMMA Health aims to make IVF less stressful, more scalable, and firmly rooted in the digital health era.

The Current IVF Monitoring Challenge

Since the late 1980s, IVF monitoring has relied on in-clinic transvaginal ultrasounds, requiring patients to visit fertility centers multiple times per cycle. These visits are often early in the morning, disrupting work, family life, and daily routines. For many, the emotional toll of repeatedly exposing intimate procedures to clinic staff adds to the anxiety of an already stressful treatment. Clinics, too, face challenges as repeated ultrasound appointments consume valuable staff time and resources, limiting their capacity to serve more patients.

IMMA Health was born from this shared frustration. Co-founders Dr. Nadia Prisant, a fertility specialist and IVF patient, and Beatrice Chemla, a healthcare strategist and mother, combined their firsthand experiences and professional expertise to envision a new model. Joined by CTO Hervé, a precision engineer, they developed a robotic, user-friendly device that enables women to safely conduct their own ultrasound scans at home without prior training.

the Innovation and Market Potential

IMMA Health’s device guides users step-by-step through transvaginal ultrasound scans, ensuring medical-grade imaging quality and safety. The system seamlessly transfers scan data to physicians who remotely review results, enabling real-time clinical decision-making without in-person visits. A pilot study is underway at Israel’s Assuta IVF Center, one of the busiest in the world, validating the device’s usability and clinical integration.

This innovation arrives at a critical moment. The global IVF market was valued at \$39.27 billion in 2025 and is forecasted to more than double to \$85.53 billion by 2034, driven by rising infertility rates, delayed parenthood, and increasing awareness. Fertility clinics worldwide are under mounting pressure to scale services without sacrificing care quality. IMMA Health’s self-operated ultrasound offers a scalable, patient-empowering solution perfectly aligned with these demands.

While major ultrasound players like GE and Philips focus on hospital equipment, no other company targets patient-operated transvaginal scans for IVF. IMMA Health is pioneering a new category by combining robust engineering, clinical insight, and regulatory rigor to bring this product to market.

What Undercode Say:

IMMA Health’s approach could mark a seismic shift in fertility care delivery by decentralizing a critical monitoring step traditionally locked into clinical settings. This democratization of IVF monitoring embodies the broader digital health trend toward patient empowerment and hybrid care models.

The founders’ deep dual perspective—clinician and patient—lends credibility and insight rarely seen in medtech startups. Dr. Nadia Prisant’s firsthand IVF journey adds emotional resonance and practical understanding to the technology design, while Beatrice Chemla’s strategic acumen bridges the gap between healthcare needs and market realities. Hervé’s engineering expertise ensures the product balances sophistication with user-friendliness and reliability.

The move to self-operated ultrasound aligns perfectly with emerging trends in digital IVF, which integrate AI-driven analytics, asynchronous consultations, and remote data collection to create more personalized and flexible care pathways. By capturing high-quality ultrasound data outside clinics, IMMA Health facilitates a richer flow of clinical information, enabling physicians to optimize treatment protocols without the logistical strain of frequent appointments.

Clinics stand to gain tremendously. The technology could free staff from routine monitoring duties, reducing scheduling pressure and operational costs while increasing patient throughput. Patients benefit from reduced stress, greater privacy, and the flexibility to conduct scans on their own schedule. This empowerment may also improve adherence to monitoring protocols, potentially enhancing clinical outcomes.

Commercially, the timing is perfect. The global fertility crisis and soaring IVF demand create a pressing need for scalable, innovative solutions. IMMA Health’s plan to launch first in the U.S., a market with high IVF volumes and advanced regulatory pathways, followed by Europe, is strategically sound. However, significant hurdles remain: securing FDA and CE approvals, scaling manufacturing, and convincing conservative fertility providers to adopt a radical new model will require relentless execution.

Competition from legacy ultrasound manufacturers is unlikely to directly challenge IMMA Health’s niche but could respond with incremental digital innovations. Startups like Pulsenmore offer at-home abdominal ultrasounds, but none match IMMA Health’s focus on self-operated transvaginal imaging tailored specifically for IVF. This specialization creates a defensible market position.

Looking forward, IMMA Health could expand into AI-assisted diagnostics, predictive analytics, and integration with fertility management platforms, further cementing their role in the digital IVF ecosystem. Their technology also opens doors to underserved populations, including those in remote areas, by overcoming geographic barriers to frequent clinic visits.

In sum, IMMA Health stands at the forefront of a fertility care revolution—transforming a grueling, clinic-bound process into an accessible, patient-centered experience. If successful, it could set a new standard for IVF monitoring worldwide.

🔍 Fact Checker Results:

✅ IMMA Health has raised \$1.1 million as reported, including a \$100,000 pre-seed round in October 2024.
✅ The device is currently in pilot use at Assuta IVF Center in Israel, one of the world’s busiest fertility clinics.
✅ The global IVF market was valued at approximately \$39.27 billion in 2025, with a CAGR forecast of 9.03% through 2034.

📊 Prediction:

IMMA Health’s self-operated robotic ultrasound system will play a pivotal role in the next decade of IVF care transformation. By 2030, hybrid IVF models incorporating home-based monitoring, AI analysis, and remote physician oversight will become standard practice in major markets. This shift will reduce patient burden and improve clinic efficiency, leading to higher IVF success rates and broader access globally. IMMA Health’s early market entry and unique product positioning give it a strong chance to become a dominant player in digital fertility care, potentially driving acquisitions or partnerships with established medical device companies eager to enter this fast-growing space.